div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: scindeks-clanciceonrssnika razvija recidiv bolesti i radika!ne cistektc:nije negativnom limfadenektomijom na definitivnom preparatu T2 stadi- je potcenjen u 40-50% a limfni evorovi src=https:reader033vdocumentspubreader033viewer20220415155e2af8de817477715020f471html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: scindeks-clanciceonrssnika razvija recidiv bolesti i radika!ne cistektc:nije negativnom limfadenektomijom na definitivnom preparatu T2 stadi- je potcenjen u 40-50% a limfni evorovi src=https:reader033vdocumentspubreader033viewer20220415155e2af8de817477715020f471html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: scindeks-clanciceonrssnika razvija recidiv bolesti i radika!ne cistektc:nije negativnom limfadenektomijom na definitivnom preparatu T2 stadi- je potcenjen u 40-50% a limfni evorovi src=https:reader033vdocumentspubreader033viewer20220415155e2af8de817477715020f471html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: scindeks-clanciceonrssnika razvija recidiv bolesti i radika!ne cistektc:nije negativnom limfadenektomijom na definitivnom preparatu T2 stadi- je potcenjen u 40-50% a limfni evorovi src=https:reader033vdocumentspubreader033viewer20220415155e2af8de817477715020f471html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 5button div class=ts-image amp-img class=ts-thumb alt=Page 5: scindeks-clanciceonrssnika razvija recidiv bolesti i radika!ne cistektc:nije negativnom limfadenektomijom na definitivnom preparatu T2 stadi- je potcenjen u 40-50% a limfni evorovi src=https:reader033vdocumentspubreader033viewer20220415155e2af8de817477715020f471html5thumbnails5jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 6button div class=ts-image amp-img class=ts-thumb alt=Page 6: scindeks-clanciceonrssnika razvija recidiv bolesti i radika!ne cistektc:nije negativnom limfadenektomijom na definitivnom preparatu T2 stadi- je potcenjen u 40-50% a limfni evorovi src=https:reader033vdocumentspubreader033viewer20220415155e2af8de817477715020f471html5thumbnails6jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 7button div class=ts-image amp-img class=ts-thumb alt=Page 7: scindeks-clanciceonrssnika razvija recidiv bolesti i radika!ne cistektc:nije negativnom limfadenektomijom na definitivnom preparatu T2 stadi- je potcenjen u 40-50% a limfni evorovi src=https:reader033vdocumentspubreader033viewer20220415155e2af8de817477715020f471html5thumbnails7jpg width=142 height=106 layout=responsive amp-img divdiv